You are here

  • Home
  • Archive
  • Volume 7, Issue 6
  • Serum 25-hydroxyvitamin D level, chronic diseases and all-cause mortality in a population-based prospective cohort: the HUNT Study, Norway

Article Text

Article menu

Download PDFPDF

XML
Epidemiology
Research
Serum 25-hydroxyvitamin D level, chronic diseases and all-cause mortality in a population-based prospective cohort: the HUNT Study, Norway
  1. Yi-Qian Sun1,
  2. Arnulf Langhammer2,
  3. Frank Skorpen1,
  4. Yue Chen3,
  5. Xiao-Mei Mai2
  1. 1 Department of Laboratory Medicine, Children's and Women's Health (LBK), Trondheim, Norway
  2. 2 Department of Public Health and Nursing, Norwegian University of Science and Technology, NTNU, Trondheim, Norway
  3. 3 School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada
  1. Correspondence to Dr Yi-Qian Sun; yi-qian.sun{at}ntnu.no

Abstract

Objective To investigate the association of vitamin D status with all-cause mortality in a Norwegian population and the potential influences of existing chronic diseases on the association.

Design A population-based prospective cohort study.

Setting Nord-Trøndelag County, Norway.

Participants A random sample (n=6613) of adults aged 20 years or older in a cohort.

Methods Serum 25-hydroxyvitamin D (25(OH)D) levels were measured in blood samples collected at baseline (n=6377). Mortality was ascertained from the Norwegian National Registry. Cox regression models were applied to estimate the HRs with 95% CIs for all-cause mortality in association with serum 25(OH)D levels after adjustment for a wide spectrum of confounding factors as well as chronic diseases at baseline.

Results The median follow-up time was 18.5 years, during which 1539 subjects died. The HRs for all-cause mortality associated with the first quartile level of 25(OH)D (<34.5 nmol/L) as compared with the fourth quartile (≥58.1 nmol/L) before and after adjustment for chronic diseases at baseline were 1.30 (95% CI 1.11 to 1.51) and 1.27 (95% CI 1.09 to 1.48), respectively. In the subjects without chronic diseases at baseline and with further exclusion of the first 3 years of follow-up, the corresponding adjusted HR was 1.34 (95% CI 1.09 to 1.66).

Conclusions Low serum 25(OH)D level was associated with increased all-cause mortality in a general Norwegian population. The association was not notably influenced by existing chronic diseases.

  • 25-hydroxyvitamin D (25(OH)D)
  • all-cause mortality
  • chronic diseases
  • prospective cohort study
  • vitamin D

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

https://doi.org/10.1136/bmjopen-2017-017256

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Strengths and limitations of this study

    • Data were from the Nord-Trøndelag Health Study 2 (HUNT2): a large population-based Norwegian cohort with long follow-up time (median 18.5 years).

    • The potential influences of existing chronic diseases on the association of serum 25-hydroxyvitamin D levels with all-cause mortality were investigated with two definitions of chronic illness respectively.

    • The observed associations remained when the analyses were performed in the subjects without chronic diseases at baseline, and with further exclusion of the first 3 years of follow-up.

    • Secondary analyses based on the imputed data for missing values of covariates produced similar association estimates.

    • Non-participation in HUNT2 (30%) may influence the generalisability of our findings.

    Introduction

    All-cause mortality is an outcome with high public health relevance. Globally, life expectancy in elderly has steadily increased over the past 30 years.1 Decline in older age mortality has been mainly the result of decreases in smoking for men and in cardiovascular disease mortality for both genders.1 Findings of new risk factors for mortality and subsequent prevention could improve life expectancy further.

    Vitamin D status has been recognised as a public health issue since low vitamin D levels are very common and may lead to the development of a wide spectrum of diseases.2–5 The pleiotropic effect of vitamin D was suggested by the presence of vitamin D synthesis enzymes and vitamin D receptors in many tissues.6 7 In addition, vitamin D is estimated to regulate 1%–3% of all gene expressions in human.8 9

    All latest meta-analyses of epidemiological studies have documented that individuals with low serum 25-hydroxyvitamin D (25(OH)D) levels are at increased risk of all-cause mortality.5 10–15 Among the meta-analysis studies a few included chronic diseases as potential confounders and found that the association estimates were similar before and after the adjustment for these variables.12 13 Nevertheless, there has been a growing concern on the possibility of reverse association between low vitamin D and existing chronic diseases leading to increased all-cause mortality.16 Thus, the aim of the current study was to investigate the association of serum 25(OH)D levels with all-cause mortality in a long-term follow-up of a Norwegian population, and to especially study the potential influences of chronic diseases as a possible confounder, effect modifier or reverse causal factor on the relationship between serum 25(OH)D levels and all-cause mortality.

    Methods

    Study design and population

    The Nord-Trøndelag Health Study (the HUNT Study) is one of the largest population-based health surveys conducted in Norway. The adult part of HUNT invited all inhabitants aged 20 years or older in the county of Nord-Trøndelag in the three separate surveys: HUNT1 (1984–1986), HUNT2 (1995–1997) and HUNT3 (2006–2008). In the current study, we used data from HUNT2 in which 65 229 subjects participated (response rate 70%). All participants in HUNT2 were invited to complete a general questionnaire including lifestyle questions, social economic status and history of chronic diseases. At the clinical examination, body weight and height were measured and blood samples were drawn for later measurement of biomarkers. We established a subcohort population (n=6613) including a 10% random sample of the HUNT2 population. Baseline serum 25(OH)D levels were measured in 6377 individuals whose blood samples were available from HUNT2. The 6377 adults (96.4% of the 6613 subjects) made up our analysis cohort.

    Measurement of serum 25(OH)D levels

    Blood samples collected in HUNT2 were stored at −70°C. Serum 25 (OH)D levels were measured using LIAISON 25-OH Vitamin D TOTAL (DiaSorin, Saluggia, Italy), a fully automated antibody-based chemiluminescence assay. The detection range of the assay is 10–375 nmol/L. The assay has an intra-assay coefficient of variation of 4% and an interassay coefficient of variation of 8%.

    Ascertainment of all-cause mortality

    The HUNT Research Centre receives updated information about deaths of all causes and emigration of the HUNT participants from the Norwegian National Registry. The Norwegian National Registry records the date of death for all people living in Norway. In the current study, the HUNT2 participants were followed up from their participation date until 15 April 2015 or the date of death.

    Information on covariates

    Baseline variables were collected by questionnaires or at clinical examination. These covariates were categorised as: age (<35, 35–44, 45–54, 55–64, 65–74 and ≥75 years), sex (female, male), season of blood draw (spring: March–May, summer: June–August, fall: September–November, winter: December–February), daily smoker (never, former, current), alcohol consumption (never, 1–4 times per month, ≥5 times per month), physical activity (inactive or very low, low, moderate, high), education (<10, 10–12, ≥13 years) and economic difficulties (During the last year, has it at any time been difficult to meet the costs of food, transportation, housing and such? yes/no). Body mass index (BMI, kg/m2) was grouped into <25.0, 25.0–29.9 and ≥30.0 kg/m2 categories according to the recommendations of the WHO.17 Chronic illness at baseline (first definition) was a variable generated from responses to a number of questions on major somatic diseases (Have you had or do you have any of the following diseases: myocardial infarction (heart attack)/angina pectoris (chest pain)/stroke (brain haemorrhage)/diabetes/cancer? yes/no). Chronic illness at baseline (second definition) was a direct variable extracted from the HUNT2 questionnaire data (Do you suffer from any long-term illness or injury of a physical or psychological nature that impairs your functioning in your everyday life (long term means at least 1 year)? yes/no). People with missing information on BMI, smoking, alcohol consumption, physical activity, education years, economic difficulties or chronic illness were regarded as an ‘unknown’ category for each variable and included in the primary analyses. The classification of each covariate has been widely used in the previous HUNT studies.18 19

    Statistical analyses

    We first tested the linearity of serum 25(OH)D levels in relation to all-cause mortality using restricted cubic spline model, which showed evidence of departure from a linear relationship (p=0.03). Therefore, 25(OH)D levels were treated as a categorical variable classified by quartiles and cut-off points (<25.0, 25.0–49.9, 50.0–74.9, ≥75.0 nmol/L) for presentation of results. The fourth quartile (≥58.1 nmol/L) and the level 50.0–74.9 nmol/L were used as the reference groups respectively since the level 50.0–74.9 nmol/L was suggested as sufficient according to the National Academy of Sciences report.20

    Cox proportional hazards regression models were applied to estimate the HRs with 95% CIs for all-cause mortality in association with serum 25(OH)D levels. Person-years were calculated from the date of participation in HUNT2 to the date when death occurred, the person emigrated out of Norway or follow-up ended (15 April 2015), whichever occurred the first. We tested proportional hazards assumption by Schoenfeld residuals for 25(OH)D levels and all covariates. Apart from sex, physical activity and economic difficulties, other variables did not show evidence against proportional hazards assumption. We therefore used the tvc option of the stcox command in Stata to model the non-proportional hazards for sex, physical activity and economic difficulties. Four multivariable models were presented to adjust confounding: model 1 adjusted for season of blood draw since serum 25(OH)D levels vary by season; model 2 adjusted for age, sex, BMI, smoking, alcohol consumption, physical activity, education and economic difficulties as potential confounders in addition to season of blood draw; model 3 adjusted for chronic illness (first definition) in addition to the variables included in model 2; model 4 adjusted for chronic illness (second definition) in addition to the variables in model 2.

    To address the issue of potential effect modification by existing chronic diseases, the association of serum 25(OH)D levels with all-cause mortality was evaluated in subgroups stratified by chronic illness (first and second definitions). To further address possible reverse association, we restricted the analyses to subjects without chronic diseases at baseline, and with additional exclusion of the first 3 years of follow-up.

    For secondary analyses, based on assumption of missing at random, missing values (‘unknown’ in tables 1 and 2) in covariates BMI, daily smoker, alcohol consumption, physical activity, education, economic difficulties and chronic illness (first and second definitions) were imputed using multivariable chained imputation with fully conditional specification (command mi impute chained in Stata). Cox proportional hazards regression was executed on 10 imputed datasets to obtain 10 sets of coefficients and SEs, and the averaged estimates were given as inferential statistics.

    View this table:
    Table 1

    Baseline characteristics of subjects in random subcohort and analysis cohort in the HUNT2 study, 1995–1997

    View this table:
    Table 2

    Overall and chronic illness-stratified distributions of serum 25(OH)D level according to baseline covariates

    All statistical analyses were performed with Stata/SE V.13.1 (College Station, Texas, USA).

    Results

    Table 1 shows that the analysis cohort (n=6377) and the random subcohort (n=6613) had similar distributions of the covariates. The median follow-up time among the 6377 adults was 18.5 years, and during the study period 1539 subjects died and 26 emigrated out of the country.

    As shown in table 2, the mean level of serum 25(OH)D in the analysis cohort was 47.3 nmol/L, with a lower level in the subjects with chronic illness (first definition) than those without chronic illness (45.2 vs 47.8 nmol/L respectively, p<0.001). In both the total cohort and the subgroup without chronic illness, multiple linear regression analysis revealed that older age, summer or fall season, more frequent alcohol consumption and higher level of physical activity were associated with higher 25(OH)D levels, whereas people with high BMI, current smoking and socioeconomic difficulties had lower levels of 25(OH)D. In the subjects with chronic illness, high BMI and current smoking remained to be associated with lower 25(OH)D levels, while male sex, summer or fall season and more frequent alcohol consumption were associated with higher levels of 25(OH)D.

    A non-linear association between serum 25(OH)D level and all-cause mortality was observed using restricted cubic spline Cox regression analysis (figure 1). It appeared that the mortality was minimised when the range of 25(OH)D was 60–100 nmol/L. There was a steady increase in the risk of death when 25(OH)D level was lower than 35 nmol/L (figure 1 and table 3).

    Figure 1
    Figure 1

    HR of all-cause mortality in association with continuous 25(OH)D levels by restricted cubic spline Cox regression analysis with five knots. Estimates were adjusted for season of blood draw, age, sex, body mass index, smoking, alcohol consumption, physical activity, education and economic difficulties, with 67.5 nmol/L as the reference value (median of the fourth quartile). 95% CIs are shown by dashed lines. 25(OH)D, 25-hydroxyvitamin D.

    View this table:
    Table 3

    The association of 25(OH)D level with all-cause mortality in different models (n=6377)

    Table 3 presents the HRs and 95% CIs for all-cause mortality in association with serum 25(OH)D levels by quartiles and cut-off points categories. In model 2, subjects with 25(OH)D in the first quartile (<34.5 nmol/L) showed an HR of 1.30 (95% CI 1.11 to 1.51) compared with those in the fourth quartile (≥58.1 nmol/L), while subjects with 25(OH)D <25.0 nmol/L showed an HR of 1.45 (95% CI 1.18 to 1.78) compared with those with 25(OH)D of 50.0–74.9 nmol/L. After adjustment for chronic illness (first definition) in model 3, HRs for the first quartile level and 25(OH)D <25.0 nmol/L changed to 1.27 and 1.41, respectively. After adjustment for chronic illness (second definition) in model 4, the corresponding HRs were slightly changed (1.30 and 1.46, respectively). In addition to the covariates in model 3, we further included systolic and diastolic blood pressures, and serum levels of total cholesterol, high-density lipoprotein and triglycerides, significant associations remained with HRs being 1.24 (95% CI 1.06 to 1.46) for the first quartile level and 1.38 (95% CI 1.12 to 1.71) for 25(OH)D level <25.0 nmol/L.

    To address the possible effect modification by chronic diseases, we evaluated the association of serum 25(OH)D levels with all-cause mortality stratified by chronic illness at baseline (table 4). The HRs for all-cause mortality associated with the first quartile level were 1.32 in the subjects without chronic illness (first definition) and 1.35 in those with chronic illness, and the corresponding HRs associated with 25(OH)D <25.0 nmol/L were 1.24 and 1.63, respectively. Stratification by chronic illness (second definition) only showed significant associations in the group with chronic diseases. However, likelihood ratio tests did not provide evidence for any effect modification by chronic illness (p>0.28 for all).

    View this table:
    Table 4

    The association of 25(OH)D level with all-cause mortality stratified by chronic illness in model 2

    Finally, to further address potential reverse association, we restricted our analyses to subjects without chronic illness (first definition) and with further exclusion of the first 3 years of follow-up (table 5). The first quartile level of serum 25(OH)D was associated with a 34% increased risk of all-cause mortality compared with the highest quartile level. Subjects with 25(OH)D level <25.0 nmol/L had a 29% increased risk of all-cause mortality compared with those with level of 50.0–74.9 nmol/L.

    View this table:
    Table 5

    The association of 25(OH)D level with all-cause mortality in subjects without chronic illness (first definition) in model 2, with further exclusion of the first 3 years of follow-up (n=5184)

    In line with the primary analyses, secondary analyses based on the imputed data for missing values of covariates including chronic illness at baseline produced similar results (see online supplementary tables 1–3).

    Supplementary Material

    Supplementary Table 1

    Discussion

    Main findings

    In this prospective study of 6377 subjects with a median follow-up period of 18.5 years, we found that the lowest 25(OH)D quartile level (<34.5 nmol/L) had a 30% increased risk of all-cause mortality compared with the fourth quartile (≥58.1 nmol/L) before adjustment for chronic illness at baseline. The subjects with 25(OH)D <25.0 nmol/L had a 45% increase in all-cause mortality compared with those with 25(OH)D of 50.0–74.9 nmol/L. The associations were not significantly confounded or modified by chronic diseases at baseline.

    Comparison with other studies

    Our findings of the association of 25(OH)D with all-cause mortality concurred with those of the meta-analysis studies .5 10–15 For the non-linear association between serum 25(OH)D level and all-cause mortality (figure 1), the range of 25(OH)D for the lowest mortality in our study was similar to that in a meta-analysis study using individual participant data and standardised vitamin D levels.13 The cut-off level of 25(OH)D for a steady increase in the risk of mortality was 35 nmol/L in our study, while it was around 40 nmol/L in this meta-analysis13. Compared with the 45% increased risk of all-cause mortality associated with 25(OH)D level <25 nmol/L observed in our study, a meta-analysis showed a 90% increased risk in association with 25(OH)D level <25 nmol/L after adjustment for age only.11 Another meta-analysis study showed a 50% increased risk of all-cause mortality in subjects with 25(OH)D level <25 nmol/L.5

    Our findings of an increased risk of all-cause mortality associated with low 25(OH)D levels were not substantially affected by having chronic diseases at baseline. This observation complies with a previous study in which no major changes in the association measures were reported after controlling for histories of chronic diseases.21 Two meta-analysis studies including individual participant data came to the same conclusion that additional adjustment for a history of chronic diseases did not alter the association of low vitamin D with increased mortality.12 13Chronic diseases included in the aforementioned studies were similar to the ones in our study, namely cardiovascular disease, diabetes and cancer.12 13 21 We also observed a similar association of low 25(OH)D levels with all-cause mortality in individuals with or without chronic illness using two different definitions. A previous research reported stronger associations in subjects without cardiovascular disease, diabetes or hypertension than those with these chronic diseases.22

    Possible mechanisms

    The association between low 25(OH) levels and increased all-cause mortality can be explained by several possible mechanisms. First, vitamin D synthesis enzymes and vitamin D receptors are present in many tissues, implying a major role of vitamin D in many physiological and pathological processes.6 7 Second, vitamin D has an important role in the regulation of proliferation, apoptosis and differentiation in many cell types, as well as functions of the immune system.8 23 Third, epidemiological studies have suggested low vitamin D level as a risk factor for a wide range of diseases from hip fractures to cardiovascular disease and cancers.3–5

    Recent research has attempted to study if there is a causal relationship between low vitamin D and all-cause mortality. A meta-analysis of Mendelian randomisation using four genetic variants around DHCR7 and CYP2R1 as instrumental variables suggested a causal effect of low levels of vitamin D on high all-cause mortality.10 In two meta-analysis studies of randomised controlled trials of relative small sample sizes, vitamin D3 supplementation reduced all-cause mortality by 6%–11% in elderly people.5 24 Results from ongoing large clinical trials25 26 are awaited to clarify the causal association of vitamin D with mortality, particularly in those with low vitamin D status prior to intervention.

    Strengths and limitations

    Selection bias seems not a big issue in our study since the analysis cohort is very similar to the subcohort of a random sample. However, non-participation in the later HUNT3 study was associated with lower socioeconomic status and higher mortality.27 Non-participation in HUNT2 presented similar problems but to a less extent, which may influence the generalisability of our findings. Serum 25(OH)D provides the most proper assessment of vitamin D status due to its longer half-life time and higher concentrations compared with the physiologically active metabolite 1,25-dihydroxyvitamin D.28 One would argue that the one-time measurement of 25(OH)D level at baseline may not reflect long-term exposure of low vitamin D. Previous studies including a Norwegian study showed that 25(OH)D concentrations were rather stable up to 14 years of follow-up.29 30 In addition, any misclassification of vitamin D due to measurement error would be non-differential as blood samples had been collected before the events occurred. Liaison immunoassay method tends to underestimate the true 25(OH)D levels.31 Thus, caution is warranted when our results are compared with studies using other assay methods or standardised 25(OH)D levels.13 32 Information about all-cause death of the Norwegian population is recorded and updated continuously at the Norwegian National Registry. The information is complete and accurate and therefore misclassification is unlikely.33

    A wide spectrum of potential confounders including chronic diseases was adjusted in the current study. Chronic diseases, on one hand, may lead to both low vitamin D levels and increased mortality.34 On the other hand, low vitamin D levels may lead to development of chronic diseases and subsequently increased mortality. Thus, chronic diseases may be either potential confounders or mediators in the causal pathway between low 25(OH)D status and all-cause mortality. No matter chronic diseases serve as a confounder or mediator, additional adjustment for this variable in model 3 and model 4 did not alter the association of 25(OH)D levels with all-cause mortality substantially. However, overadjustment may be possible if chronic diseases were in the pathway. Neither did we find significant effect modification by chronic illness defined by two definitions. Possibility of reverse association between low vitamin D and chronic diseases has been a main concern in the assessment of the vitamin D and mortality association.16 Nevertheless, the association remained when we restricted the analysis in the subjects without chronic diseases at baseline and with further exclusion of the first 3 years of follow-up. In agreement with a previous study,35 our results suggest that low vitamin D level is an important risk factor for all-cause mortality independent of ill health at baseline.

    Apart from the limitations, our study is among the few to highlight and thoroughly investigate the potential influences of chronic diseases on the association of low vitamin D with all-cause mortality.

    Conclusions

    Overall, we found that low serum 25(OH)D level was associated with an increased risk of all-cause mortality in a general Norwegian population. The association was not notably influenced by existing chronic diseases. Results from the ongoing large clinical trials are being awaited to clarify a causal relationship.

    Acknowledgments

    The Nord-Trøndelag Health Study (HUNT) is a collaboration between the HUNT Research Centre (Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology), the Nord-Trøndelag County Council and the Norwegian Institute of Public Health. The authors especially thank the HUNT Research Centre laboratory personnel for the measurement of serum 25(OH)D levels.

    References

    1. 1.↵
      2. Mathers CD ,
      3. Stevens GA ,
      4. Boerma T , et al
      . Causes of international increases in older age life expectancy. Lancet 2015;385:540–8.doi:10.1016/S0140-6736(14)60569-9
      OpenUrlCrossRefPubMedWeb of Science
    2. 2.↵
      2. Palacios C ,
      3. Gonzalez L
      . Is vitamin D deficiency a Major global public health problem? J Steroid Biochem Mol Biol 2014;144:138–45.doi:10.1016/j.jsbmb.2013.11.003
      OpenUrlCrossRefPubMed
    3. 3.↵
      2. de Boer IH ,
      3. Levin G ,
      4. Robinson-Cohen C , et al
      . Serum 25-hydroxyvitamin D concentration and risk for Major clinical disease events in a community-based population of older adults: a cohort study. Ann Intern Med 2012;156:627–34.doi:10.7326/0003-4819-156-9-201205010-00004
      OpenUrlCrossRefPubMedWeb of Science
    4. 4.↵
      2. Wang TJ ,
      3. Vitamin D ,
      4. Disease C
      Annu Rev Med 2016;67:261–72.
      OpenUrl
    5. 5.↵
      2. Chowdhury R ,
      3. Kunutsor S ,
      4. Vitezova A , et al
      . Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies: BMJ Publishing Group , 1903.
    6. 6.↵
      2. Uhlén M ,
      3. Fagerberg L ,
      4. Hallström BM , et al
      . Proteomics. Tissue-based map of the human proteome. Science 2015;347:1260419.doi:10.1126/science.1260419
    7. 7.↵
      2. Uhlen M ,
      3. Oksvold P ,
      4. Fagerberg L , et al
      . Towards a knowledge-based human protein Atlas. Nat Biotechnol 2010;28:1248–50.doi:10.1038/nbt1210-1248
      OpenUrlCrossRefPubMed
    8. 8.↵
      2. Holick MF
      . Vitamin D deficiency. N Engl J Med 2007;357:266–81.doi:10.1056/NEJMra070553
      OpenUrlCrossRefPubMedWeb of Science
    9. 9.↵
      2. Ramagopalan SV ,
      3. Heger A ,
      4. Berlanga AJ , et al
      . A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res 2010;20:1352–60.doi:10.1101/gr.107920.110
      OpenUrlAbstract/FREE Full Text
    10. 10.↵
      2. Afzal S ,
      3. Brøndum-Jacobsen P ,
      4. Bojesen SE , et al
      . Genetically low vitamin D concentrations and increased mortality: mendelian randomisation analysis in three large cohorts. BMJ 2014;349:g6330.doi:10.1136/bmj.g6330
      OpenUrlAbstract/FREE Full Text
    11. 11.↵
      2. Garland CF ,
      3. Kim JJ ,
      4. Mohr SB , et al
      . Meta-analysis of all-cause mortality according to serum 25-hydroxyvitamin D. Am J Public Health 2014;104:e43–e50.doi:10.2105/AJPH.2014.302034
      OpenUrlPubMed
    12. 12.↵
      2. Schöttker B ,
      3. Jorde R ,
      4. Peasey A , et al
      . Vitamin D and mortality: meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States. BMJ 2014;348:g3656.doi:10.1136/bmj.g3656
      OpenUrlAbstract/FREE Full Text
    13. 13.↵
      2. Gaksch M ,
      3. Jorde R ,
      4. Grimnes G , et al
      . Vitamin D and mortality: individual participant data meta-analysis of standardized 25-hydroxyvitamin D in 26916 individuals from a european consortium. PLoS One 2017;12:e0170791.doi:10.1371/journal.pone.0170791
    14. 14.↵
      2. Schöttker B ,
      3. Ball D ,
      4. Gellert C , et al
      . Serum 25-hydroxyvitamin D levels and overall mortality. A systematic review and meta-analysis of prospective cohort studies. Ageing Res Rev 2013;12:708–18.doi:10.1016/j.arr.2012.02.004
      OpenUrlCrossRefPubMedWeb of Science
    15. 15.↵
      2. Zittermann A ,
      3. Iodice S ,
      4. Pilz S , et al
      . Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies. Am J Clin Nutr 2012;95:91–100.doi:10.3945/ajcn.111.014779
      OpenUrlAbstract/FREE Full Text
    16. 16.↵
      2. Autier P ,
      3. Boniol M ,
      4. Pizot C , et al
      . Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol 2014;2:76–89.doi:10.1016/S2213-8587(13)70165-7
      OpenUrlCrossRefPubMed
    17. 17.↵
      Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000;894253:1.
      OpenUrl
    18. 18.↵
      2. Brumpton BM ,
      3. Langhammer A ,
      4. Ferreira MA , et al
      . Physical activity and incident asthma in adults: the HUNT Study, Norway. BMJ Open 2016;6:e013856.doi:10.1136/bmjopen-2016-013856
    19. 19.↵
      2. Mai XM ,
      3. Langhammer A ,
      4. Chen Y , et al
      . Cod liver oil intake and incidence of asthma in norwegian adults--the HUNT study. Thorax 2013;68:25–30.doi:10.1136/thoraxjnl-2012-202061
      OpenUrlAbstract/FREE Full Text
    20. 20.↵
      2. Ross AC ,
      3. Taylor CL ,
      4. Yaktine AL , et al
      ; Dietary Reference Intakes for calcium and vitamin D. Washington, DC: BMJ Publishing Group, 2011..
    21. 21.↵
      2. Ford ES ,
      3. Zhao G ,
      4. Tsai J , et al
      . Vitamin D and all-cause mortality among adults in USA: findings from the National Health and Nutrition Examination Survey Linked Mortality Study. Int J Epidemiol 2011;40:998–1005.doi:10.1093/ije/dyq264
      OpenUrlCrossRefPubMed
    22. 22.↵
      2. Melamed ML ,
      3. Michos ED ,
      4. Post W , et al
      . 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008;168:1629–37.doi:10.1001/archinte.168.15.1629
      OpenUrlCrossRefPubMedWeb of Science
    23. 23.↵
      2. Feldman D ,
      3. Krishnan AV ,
      4. Swami S , et al
      . The role of vitamin D in reducing Cancer risk and progression. Nat Rev Cancer 2014;14:342–57.doi:10.1038/nrc3691
      OpenUrlCrossRefPubMedWeb of Science
    24. 24.↵
      2. Bjelakovic G ,
      3. Gluud LL ,
      4. Nikolova D , et al
      ; Vitamin D supplementation for prevention of mortality in adults. : BMJ Publishing Group, 2014:Cd007470. (published Online First: 15 Jan 2015).
    25. 25.↵
      2. Kupferschmidt K
      . Uncertain verdict as vitamin D Goes on trial. Science 2012;337:1476–8.doi:10.1126/science.337.6101.1476
      OpenUrlAbstract/FREE Full Text
    26. 26.↵
      2. Pilz S ,
      3. Rutters F ,
      4. Dekker JM
      . Disease prevention: vitamin D trials. Science 2012;338:883.doi:10.1126/science.338.6109.883-c
    27. 27.↵
      2. Langhammer A ,
      3. Krokstad S ,
      4. Romundstad P , et al
      . The HUNT study: participation is associated with survival and depends on socioeconomic status, diseases and symptoms. BMC Med Res Methodol 2012;12:143.doi:10.1186/1471-2288-12-143
      OpenUrlCrossRefPubMed
    28. 28.↵
      2. Zerwekh JE
      . Blood biomarkers of vitamin D status. Am J Clin Nutr 2008;87:1087s–91.
      OpenUrlPubMed
    29. 29.↵
      2. Jorde R ,
      3. Sneve M ,
      4. Hutchinson M , et al
      . Tracking of serum 25-hydroxyvitamin D levels during 14 years in a population-based study and during 12 months in an intervention study. Am J Epidemiol 2010;171:903–8.doi:10.1093/aje/kwq005
      OpenUrlCrossRefPubMedWeb of Science
    30. 30.↵
      2. Schöttker B ,
      3. Haug U ,
      4. Schomburg L , et al
      . Strong associations of 25-hydroxyvitamin D concentrations with all-cause, cardiovascular, Cancer, and respiratory disease mortality in a large cohort study. Am J Clin Nutr 2013;97:782–93.doi:10.3945/ajcn.112.047712
      OpenUrlAbstract/FREE Full Text
    31. 31.↵
      2. Schöttker B ,
      3. Jansen EH ,
      4. Haug U , et al
      . Standardization of misleading immunoassay based 25-hydroxyvitamin D levels with liquid chromatography andem-mass spectrometry in a large cohort study. PLoS One 2012;7:e48774.doi:10.1371/journal.pone.0048774
    32. 32.↵
      2. Binkley N ,
      3. Sempos CT
      ; Vitamin D Standardization Program (VDSP). Standardizing vitamin D assays: the way forward. J Bone Miner Res 2014;29:1709–14.doi:10.1002/jbmr.2252
      OpenUrlCrossRefPubMed
    33. 33.↵
      Norwegian National Registry 2017. http://www.skatteetaten.no/en/person/National-Registry/ (cited 19 Nov 2016).
    34. 34.↵
      2. Autier P
      . Vitamin D status as a synthetic biomarker of health status. Endocrine 2016;51:201–2.doi:10.1007/s12020-015-0837-x
      OpenUrlCrossRefPubMed
    35. 35.↵
      2. Schöttker B ,
      3. Saum KU ,
      4. Perna L , et al
      . Is vitamin D deficiency a cause of increased morbidity and mortality at older age or simply an Indicator of poor health? Eur J Epidemiol 2014;29:199–210.doi:10.1007/s10654-014-9894-3
      OpenUrlPubMed

    Footnotes

    • Contributors YQS, AL, YC and XMM contributed to the study design. XMM and AL contributed to data collection. YQS conducted statistical analyses, interpreted results and wrote the initial draft of the manuscript. AL, FS, YC and XMM participated in the data interpretation and helped write the final draft of the manuscript.

    • Funding This work (the research position of YQS) was supported by funding from The Norwegian Cancer Society (project ID 5769155-2015) and The Research Council of Norway ‘Gaveforsterkning’.

    • Competing interests None declared.

    • Patient consent All participants gave their informed consent on participation in HUNT, linkage to previous HUNT surveys and specific registries.

    • Ethics approval The study was approved by the Norwegian Regional Committees for Medical and Health Research Ethics.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Data sharing statement No additional data available.